# Naoxintong Capsule for Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialAcronymNXT-DKD

Study · id `cardio:ct-nct07698223` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07698223](<https://clinicaltrials.gov/study/NCT07698223>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07698223

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 410 participants.

## Technical summary

Registry record NCT07698223. Randomized; double masking; primary purpose treatment. Start 2027-03-01 (anticipated); primary completion 2028-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 410 participants (planned count; ClinicalTrials.gov record NCT07698223, source copy `cardio:ctgov-nct07698223-2026-07-13`, retrieved 2026-10-26)
- Planned start: 2027-03-01 (anticipated) (ClinicalTrials.gov record NCT07698223, source copy `cardio:ctgov-nct07698223-2026-07-13`, retrieved 2026-10-26)
- Primary completion: 2028-06-01 (anticipated) (ClinicalTrials.gov record NCT07698223, source copy `cardio:ctgov-nct07698223-2026-07-13`, retrieved 2026-10-26)
- Completion: 2028-12-30 (anticipated) (ClinicalTrials.gov record NCT07698223, source copy `cardio:ctgov-nct07698223-2026-07-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07698223, source copy `cardio:ctgov-nct07698223-2026-07-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07698223-2026-07-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Naoxintong Capsule for Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialAcronymNXT-DKD
- Acronym: NXT-DKD
- Condition: Diabetic Nephropathy
- Intervention (Drug): Naoxintong Capsule
- Intervention (Drug): Placebo
- Lead sponsor: Chen Xiangmei
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 6949eb6533f27ab275a9337bab7774a5decacb3ceb16cc5a37798b9d894d32ef
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
